• Founded by two career biotech veterans who had perfected grape cultivation and were ready to further diversify their organic farm
• The climate in Sonoma County is ideal for grapes and also for cannabis
• Produces premium quality cannabis at a fraction of the cost of its competitors

Sonoma Biologics, an ultra-premium cannabis grower located in California wine country, was founded by Paul Caracciolo and his wife, Margaret, both out of the biotech industry.  They founded Mill Station Vineyards in Sonoma, planning to perfect their winemaking craft, and establish an organic farm, according to an article in USA Today (https://ibn.fm/3Ysr7). With 8.5 acres of ultra-premium Pinot Noir grapes, they began to gain a reputation and world-class winemakers started buying their grapes. Their grapes can be found in some of the most coveted Pinot Noirs in the Russian River Valley of Sonoma county. Having worked in the biotech industry and seeing the world through the lens of science, they viewed Sonoma as a laboratory. This influenced everything they did and helped them develop standard protocols for cultivation that were precisely calibrated to create the high-quality grapes they now grow. The climate in Sonoma County is ideal for grapes and also, as it turned out, for cannabis as well. In 2016 California approved the 2016 voter initiative to legalize cannabis. Paul and Margaret knew they were well-positioned to diversify and enter one of the fastest-growing industries in the region. When they decided to move into cultivating cannabis, the two applied the same basic principles they used in the growing of grapes. Just as other winemakers came to them for their grapes, Cannabis start-ups reached out to them for varietal knowledge in Sonoma county, as the Caracciolos had already tested and piloted tens of varietals in their first year for climate suitability. “There are a lot of analogies when it comes to irrigating and scaling these two farming products,” said Caracciolo. “Having grown grapes on the scale we had been, really gave us a head start in the cannabis business. All other factors being equal, it can’t be overstated that being enthusiastic and passionate about your products isn’t enough. It really helps to know and understand the science to take your product to the next level.” Sonoma Biologics adheres to the strictest standards required by both the California Department of Agriculture and the Sonoma county agricultural standards and regulations. The Company has successfully passed California’s laboratory purity testing for the past three years. By using exclusively organic methods to grow and taking advantage of the suitable Sonoma county climate, the Company produces premium quality crops at a fraction of the cost of its competitors. Sonoma Biologics has acquired land in Sonoma County and Mendocino County, with additional expansion targeted for Lake County. The goal is to become one of the largest organic-equivalent, environmentally friendly suppliers in northern California through acquisitions, joint ventures, and revenue-sharing cultivation opportunities. With years of experience in large-scale commercial farming, including 100 acres of hemp grown in 2019, the team at Sonoma Biologics is well-positioned to expand rapidly towards a vertically integrated operation. For more information, visit the company’s website at www.OwnSonomaBiologics.com. NOTE TO INVESTORS: The latest news and updates relating to Sonoma are available in the company’s newsroom at https://ibn.fm/Sonoma

• BRSF made strides on operations front to improve lead times, quality control
• Company experienced revenue growth, increase in assets and R&D
• Brain Scientific has identified that only 30% of U.S. hospitals have equipment for routine EEGs due to cost and space constraints

Brain Scientific (OTCQB: BRSF), a commercial-stage, health-care company, announced it has filed its annual report for the fiscal year that ended Dec. 31, 2020 (https://ibn.fm/GCazt). The company reported key business highlights and substantial growth as well as outlined milestones expected to be completed over the next two years. “In 2020, Brain Scientific made good progress toward our vision of introducing transformative brain diagnostic solutions that apply cutting-edge technologies and establish a new innovative norm for clinicians,” said Boris Goldstein, chairman of the board of directors. “We made strides on the operations front to improve lead times and quality control, as well as connections to expand our customer base in early 2021.” From 2019 to 2020, BRSF experienced a revenue growth from $489,202 to $544,275, and an increase in assets from $291,002 to $440,218. The company’s liabilities also increased, with 80% of the increase coming from the addition of derivative liabilities and convertible notes payable. The research and development efforts of the company also increased, up an impressive 266% from the previous year. The company’s two FDA-cleared products, the NeuroCap(TM) and NeuroEEG(TM), will soon be manufactured in the United States, with a rollout to follow in the Canadian market. Currently, both devices are available on a limited basis to ICUs, acute care settings and other emergency departments throughout the country. Brain Scientific has developed innovative products that are disrupting the EEG norms. The NeuroCap, a disposable pre-gelled headset, is disposable and easy to set up. It offers a cost-effective EEG solution to obtain rapid EEGs in routine clinical and research settings where recording of STAT EEGs is desired. The NeuroEEG is a portable, wireless and cost-effective EEG system that fits in the palm of a hand, and requires minimal training to use. Throughout 2020 and the global pandemic, the need for disposable, easy, and quick-to-use EEG options became even more evident. The NeuroCap and NeuroEEG help minimize contact between patients and the medical worker, provide a more sanitary solution, and can be used in a broad variety of settings. In fact, BRSF has identified that only 30% of U.S. hospitals have equipment for routine EEGs due to cost and space constraints. The devices’ accessibility and quality have made it ideal for use in R&D as well, from concussion research (https://ibn.fm/ybdot) to potentially uncovering new treatment options to reduce autism symptoms in children (https://ibn.fm/1zraT). For more information, visit the company’s website at www.BrainScientific.com/Invest-Now. NOTE TO INVESTORS: The latest news and updates relating to BRSF are available in the company’s newsroom at https://ibn.fm/BRSF

• Simple design enables consumers to prevent medication errors
• Offers 12 different functionalities with the newest addition of GoodRX
• Now offering up to 85% discount on most medications at over 70,000 pharmacies Across the United States. Powered by GoodRX
• Download the APP now and not only manage your medication but save money every time you walk into your local Pharmacy by having your coupons ready

United Medical Equipment Business Solutions Network (“UME”) is in the business of helping families with medical resources, supplies and providing a network of reliable solutions. One of these solutions is the Medication Management App, developed to provide direct and indirect patient care and education for care professionals, caregivers, students, and family members. The simple design enables consumers to prevent medication errors by providing quick information in the convenience of one available app on the iOS and Android platforms.

The free initial download allows for basic app functionalities. These include access to:

• Medication Dictionary
• Pill Identifier
• Weight Converter
• Temperature Converter
• Volume Converter
• Height Converter
• Dosage Converter

A monthly subscription fee or discounted yearly fee unlocks the professional functions that include:

• Y-Site IV Compatibility
• HIPAA Secure Messenger
• Medication Log-Reminder
• Good RX
• UME Elite Education

GoodRX is the newest addition to the app’s functions. This feature allows users to view discount prices and coupons while managing medications all within the app. Without leaving the Medication Management App, the user can compare prices between pharmacies, access free coupons for their prescriptions, and show the coupon to the pharmacist when picking up the prescription. All of this without having to leave the one convenient app location.

Coupons and discounts for prescriptions are not all that GoodRx brings to the Medication Management App. In addition, GoodRX offers same-day appointments with an online healthcare provider, access to at-home lab tests or tests at a nearby service center, and all at minimal costs. The company also brings additional information to the platform that has been reviewed for accuracy by medical and healthcare experts. Articles span from healthy living and disease management to healthcare costs and ways to save.

The Medical Management App is one more way that United Medical Equipment is providing reliable resources and solutions to fit the ever-changing needs of an aging population.

For more information, visit the company’s website at www.UnitedMedSolutions.com.

NOTE TO INVESTORS: The latest news and updates relating to United Medical Equipment are available in the company’s newsroom at https://ibn.fm/UnitedMed

• Bell2Bell podcast features company CEO, CFO, CTO of Helomics subsidiary
• POAI is “in probably the best situation we’ve been in since the existence of the company,” reports CFO
• Company anticipates revenue from its unique PeDAL platform

Three Predictive Oncology (NASDAQ: POAI) executives were featured guests on a recent Bell2Bell podcast (https://ibn.fm/DumLs). Newly appointed CEO Mel Engle, CFO Bob Myers and Mark Collins, chief technical officer of the company’s Helomics subsidiary, shared updates regarding POAI’s financial footing, current operations and goals for 2021 during the podcast, which delivers informative updates and exclusive interviews with executives operating in fast-moving industries. Named Predictive Oncology’s new CEO in March, Engle provided a summary of his journey to becoming head of the precision medicine company. “I’ve been on the board of Predictive Oncology for about four years, and within the last year and a half, I’ve been the chairman of the board,” he said. “Being in that kind of position, it’s easier for me to be able to step into this role.” In addition to his POAI expertise, Engle noted that he has filled the roles of CEO in several previous companies, including Merck subsidiary and pharmaceutical company Dey Laboratories. “We were a $610 million company when sold to Mylan back in 2007,” he continued. “That was a pharmaceutical respiratory company, so I’m very familiar with the ins-and-outs of R&D and the notion of what Predictive Oncology is doing.” During his remarks, Myers reported that from a financial standpoint, POAI is “in a great situation, probably the best situation we’ve been in since the existence of the company, in terms of our cash capability and the strength of our balance sheet, and the fact that we have a lot of things going on . . . in terms of the income that we expect to get this year and the projects that we have,” he said. “We are going into these projects in the strength position.” Collins then provided an update on POAI’s Helomics, noting that one of the most important projects the company is working on — and that it expects to see revenue results from — is its PeDAL platform, or patient-centric drug discovery using active learning. PeDAL is a unique technology that combines a proprietary, clinically validated patient tumor cell line assay with a vast knowledge base of proprietary and public data together with active learning (https://ibn.fm/ivRKP). “What this platform does is it’s a fee-for-service platform for pharmaceutical companies to test their drugs against our cancer cell lines, like doing, if you will, a clinical trial in a plastic dish,” said Collins. “Because we have all these patient cell lines that we have knowledge of . . .  what drug they were treated with and so on. And we believe this will revolutionize the way that pharma does drug discovery.” Collins also reported that, earlier this year, the company launched an internal drug repositioning project where POAI is actually testing known anti-cancer drugs against its patient cell lines, driven by the machine learning. The project is designed “to generate some proof data for the platform that’s important for commercial discussion but also to generate some valuable intellectual property about those compounds and their activity against specific tumors and specific patient profiles,” said Collins. “Again, that puts us firmly in the AI drug-discovery category, which is where the analysts. . . have indicated that we are a potential emerging player, with a very strong potential in that space.” POAI is bringing precision medicine, or tailored medical treatment using the individual characteristics of each patient, to the treatment of cancer. Through its Helomics division, the company leverages its unique, clinically validated patient derived (“PDx”) smart tumor profiling platform to provide oncologists with a roadmap to help individualize therapy. In addition, the company is leveraging artificial intelligence and its proprietary database of more than 150,000 cancer cases tumors to build AI-driven models of tumor drug response to improve outcomes for the patients of today and tomorrow. For more information, visit the company’s website at www.Predictive-Oncology.com. NOTE TO INVESTORS: The latest news and updates relating to PULL are available in the company’s newsroom at http://ibn.fm/POAI

• CBD-infused products market is expected to grow 48.1% annually to reach $165.7 billion by 2027
• Pure Extracts Technologies’ subsidiary recently began production of goods expected to generate approximately $950,000 in revenue
• New tolling agreement is for extraction of 80-85% pure CBD distillate from an initial 500 kilograms (~1,102 pounds) of hemp biomass

Any industry forecast for double-digit growth is one worth keeping an eye on. When experts are calling for mid-double-digit annual market growth, like that of CBD-infused products, it’s worth a head turn and a stare. Meticulous Research this month forecast this market to experience compound annual growth of 48.1% from 2020 to 2027 to reach $165.7 billion. That falls right into the sweet spot for Pure Extracts Technologies (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ), a plant-based extraction company focused on cannabis, hemp, functional mushrooms, and the burgeoning psychedelic sector. The protracted demand for CBD, an acronym for cannabidiol, aligns with the Company’s strategy to leverage sales for legal cannabis and hemp products while the psychedelic markets develop.

A first mover with highly technical expertise in plant extraction processes, the Company operates a purpose-built EU GMP compliant facility north of Whistler, British Columbia. Business has been booming for Pure Extracts. During a span of eight days, the Company announced commencing production of approximately 50,000 Pure Chews edible gummie packs and then 25,000 vape cartridges for the Canadian retail markets. Cumulatively, the production runs were estimated to produce about $950,000 in revenue for the Company (https://ibn.fm/xCKKE).

Only a few days after that news, the Company said it landed a new tolling agreement for the extraction of 80-85% pure CBD distillate from an initial 500 kilograms (~1,102 pounds) of hemp biomass (https://ibn.fm/D0Qrf). Tolling agreements are contracts to put a specified amount of raw material through a processing facility during a certain period of time for a fixed price.

As it happened, the three separate developments demonstrated Pure Extracts’ growth verticals for in-house brands and toll processing, which complement a third avenue of white labeled products for partners.

The biomass was sourced from one of Pure Extracts’ preferred suppliers and has a CBD potency of just over 10 percent. This biomass, with its specific particulate mill size, runs very efficiently on Pure Extracts’ Vitalis R200 sub/super-critical CO2 extraction system. Once processed, the high degree of purity in the CBD extract makes it an ideal ingredient for any number of finished consumer goods, such as topicals, beverages, edible gummies, chocolates and vape cartridges.

“We are pleased to have entered into this tolling agreement and to have taken delivery of the first 500 kg of milled hemp biomass,” said Pure Extracts CEO Ben Nikolaevsky in a statement. “We are very familiar with this particular biomass having used it before in the manufacturing of our in-house, branded products, so we know it extracts very well,” he added.

For more information, visit the company’s website at www.PureExtractsCorp.com.

NOTE TO INVESTORS: The latest news and updates relating to PULL are available in the company’s newsroom at https://ibn.fm/PULL

• Fan Pass new artist signups and live channel activations continued to increase in April
• Friendable expects to release version 2 of Fan Pass during June 2021
• A signed letter of intent between Friendable and Santo Blockchains Labs and Santo Mining Corp. will help provide artists with an additional form of revenue – NFTs
• The music streaming industry is expected to reach $12.36 billion by 2025

Friendable (OTC: FDBL) announced that the final total number of new artist signups to its Fan Pass platform in April 2021 reached 946, a 65% increase over the March 2021 signups. These additional signups are one milestone in a long string of company achievements since Fan Pass was released in July 2020. Additionally, live channel activations rose by 2,250% in April, building on the foundation set by March successes, as the company tests new technological enhancements and onboarding features as part of version 2 of the Fan Pass Live Streaming platform (https://ibn.fm/2qQDQ). The upgrades being tested offer artist members near-instant gratification, which has helped propel growth across all facets of the operation. Other Fan Pass metrics also continue to see rising numbers, proving Friendable’s continued efforts to provide enhancements across other platform levels geared toward promoting overall growth. Alongside social media followers, artist testimonials, and the positive recognition of the Fan Pass brand, the company focuses on providing the necessary awareness and assistance needed by the developing artists on the platform. According to a recent statement from Friendable Inc. CEO Robert A. Rositano Jr. discussing the upcoming version 2 of the platform, the Fan Pass team “has listened, tweaked, and redesigned where needed and added features that can only accelerate our next push to the market. We are looking forward to many exciting developments on the horizon. We expect to be announcing our release of v2 sometime in June 2021,” Rositano Jr. added. Fan Pass is a free artist platform that is centrally focused on the relationship between artists and the fans that fuel them. The platform allows for artists to earn revenue on fan subscriptions, merchandise sales and any live ticket-based online performances. All the monetary earnings for the artist can be monitored from their exclusive Fan Pass artist dashboard. In addition to the traditional means of revenue, Friendable has taken steps to provide global entertainment and musical artist-driven non-fungible tokens (“NFTs”) and has already signed a letter of intent with Santo Blockchain Labs and Santo Mining Corp. (OTC: SANP) for their development. NFTs are units of data stored in a digital ledger (blockchain) certifying the uniqueness of the digital asset. NFTs can be used to represent items including, but not limited to, photos, audio, video, and other digital-based files. “This agreement with Santo should bring some serious excitement to our artists, which we believe will also add a unique and creative component to our business model, current artist offering, and revenue opportunities moving forward,” Rositano Jr. explained (https://ibn.fm/6f7n9). These advancements and new offerings are cementing Friendable’s strong position in expanding music streaming market. With the uncertainty of the COVID-19 pandemic still a deciding factor in many in-person events, streaming has filled the gap created by the virus. Even when in-person events are resumed, the music streaming market is not expected to slow anytime in the future, as many performances will most likely still be livestreamed, as well. By the end of 2021, U.S. music streaming revenue is projected to reach $8.67 billion. The figure is expected to continue growing at a CAGR of 9.27% from 2021-2025, reaching $12.36 billion by 2025. User penetration for 2021 is expected to reach 30.2% and round out the forecast period reaching 40.1% (https://ibn.fm/gSH6Q). Friendable and the Fan Pass platform are leveraging the numerous opportunities emerging from music streaming industry, offering new engagement possibilities for performing artists and the fans who follow them. For more information, visit the company’s websites at www.Friendable.com or www.FanPassLive.com. NOTE TO INVESTORS: The latest news and updates relating to FDBL are available in the company’s newsroom at http://ibn.fm/FDBL

• Smart technologies are enabling a new era of intelligent-tech customer services as up to 90 percent of the world’s population is expected to be using smart devices with smart assistant functions in the next few years
• Beijing-based AI solutions company Infobird recently closed its IPO on the NASDAQ exchange to demonstrate its widening reach in delivering intelligent B2B services
• The company has 70 IP rights developed under its cloud-native architecture and AI technologies
• Infobird’s B2B services provide a no-code development platform to help companies focus their efforts and financial outlays where they are most needed in multiple levels of customer service, marketing and management

A mere two decades after the Internet began to insinuate itself into individuals’ everyday lives and 14 years since the launch of Apple’s iPhone introduced the world to touchscreens and truly “smart phones,” the business of buying goods and services is becoming dependent on intelligent technologies and has more of a global outlook than ever.

Artificial intelligence (“AI”) solutions company Infobird (NASDAQ: IFBD), which also was established two decades ago, is demonstrating its commitment to pioneering the next stage of intelligent B2B customer services with its recent debut on The Nasdaq Capital Market, where it plans to raise funding primarily for marketing and technology research and development that widens the number of fields where innovative technologies are used (https://ibn.fm/BoHfd).

On the first day of trading last month, “Infobird Software’s stock triggered a circuit break several times and once rose to a high of 11.25 US dollars,” demonstrating the market’s interest in Infobird’s reputation as a premier provider of customer engagement solutions in China and belief in the value of intelligent and proactive of customer interaction in the customer relationship management as a whole, according to the Google translation of the company’s April 21 Chinese news release (https://ibn.fm/fRiNo).

“Infobird Software pioneered the cloud computing call center, created China’s leading intelligent customer service system, introduced the digital intelligent customer business philosophy, and built a nationwide customer operation and service system, using independent research and development. Technology and excellent products have served more than 70,000 enterprises,” CEO Yimin Wu stated in the news release. “Listing (on Nasdaq) is not the end, it is a new starting point, which means more opportunities and greater responsibilities.”

The news release adds that the new market listing will help Infobird accelerate its global deployment with the support of full-stack and full-chain service capabilities while becoming more open and inclusive to elements beyond its current operating borders.

Infobird is primarily directed toward key corporations in the finance industry but its expansion is demonstrated by its past experiences with clients from other industries as well, such as e-commerce giant Alibaba (NYSE: BABA).

Infobird has 70 independent intellectual property (“IP”) rights backing its self-developed cloud native architecture and AI technologies, serving banking, insurance, medical, retail and other industries.

The present pandemic society influencing the world’s economies has driven intelligent customer technologies higher at an energetic rate. As a recent CIO magazine commentary notes, this effect “can be seen across life, work, and society as industrial applications begin to solve our most pressing issues.”

The article notes that, according to Huawei’s Global Industry Vision (“GIV”) 2025 predictions, an estimated 97 percent of global enterprises will implement digital transformation through intelligent upgrades within the next few years, and that a “staggering” 90 percent of the world’s population will use smart devices with smart assistant functions while global smart home appliances use will grow to 20 billion aided by the integration of big data, AI, cloud computing and 5G network speeds.

“The twenty-year-old Infobird is a young man. We are not short of passion and drive. We hope to open up an unprecedented new path in the field of AI customer business, release more energy under the tide of economic globalization, and contribute to business and society,” Wu stated in the news release.

For more information, visit the company’s website at www.Infobird.com/en/index.html

NOTE TO INVESTORS: The latest news and updates relating to IFBD are available in the company’s newsroom at https://ibn.fm/IFBD

• Pac Roots Cannabis completed acquisition of Lords of Grasstown Holdings on February 19, 2021
• Acquisition will provide Pac Roots with foothold in lucrative Californian cannabis market, broaden its product portfolio
• Californian cannabis market generated total sales of $4.4 billion in 2020, more than double C$2.6bn value of the entire Canadian market last year

On February 19, 2021, Pac Roots Cannabis (CSE: PACR) (OTCQB: PACRF) (FSE: 4XM) announced the closing of a share purchase agreement with the shareholders of Lords of Grasstown Holdings Ltd., a well-established cannabis motorcycle lifestyle brand with a tremendous following within the motorcycle and legal cannabis communities (https://ibn.fm/pqdNY).  Whilst the acquisition is undoubtedly significant in terms of broadening out Pac Roots’ product portfolio, it also heralds Pac Root Cannabis’ entry into the lucrative United States legal cannabis market. The Lords of Grasstown brand was initially founded in 2013, designed to build upon the success of Lords of Gastown, a lifestyle and apparel brand originally founded in Canada’s Pacific Northwest and which subsequently expanded into California as of 2015. Created to fulfil a growing demand niche, the Lords of Grasstown brand started off by offering street wear apparel and related products, such as a Fight Club-inspired CBD soap line. The brand would later go on to partner with premium Canadian cannabis suppliers in a bid to introduce some of Canada’s highest testing medical cannabis strains within their product portfolio (https://ibn.fm/et6Ac). The state of California legalized the recreational adult use of cannabis in late 2016. Since then, the Californian cannabis market has grown at an astounding rate, with sales rising to $4.4 billion in 2020 (https://ibn.fm/3ScUa), up 57% relative to the previous year.  To put that figure into perspective, the entire Canadian legal cannabis market generated gross sales of C$2.6 billion ($2.09 billion) in 2020, less than half the figure achieved in the state of California alone (https://ibn.fm/tU0x7). Pac Roots Cannabis has thus far focused its efforts on the Canadian market, having successfully gathered an initial harvest of 105,000 pounds of biomass earlier this year, as part of its British Columbia-centered joint venture with Rock Creek Farms. At the time, PACR revealed that its harvest is being processed and sold in its entirety to the Speakeasy Cannabis Club (CSE: EASY) at a healthy profit margin (https://ibn.fm/8F2Kt). Pac Roots has subsequently sought to expand production, most recently through the acquisition of a substantial, 250-acre restriction-free plot of land in the Fraser Valley—one of the most intensely farmed and productive agricultural districts in Canada. From an early date, Pac Roots has looked to differentiate itself from competitors through the relentless pursuit of a genetics-based cultivation approach, which has enabled the Company to produce 50 super-elite strains and roughly 350 tested cultivars. That in turn has resulted in PACR maximizing its yields while simultaneously boosting profitability and minimizing labor costs. With the Company now poised to enter the highly lucrative Californian cannabis market, PACR’s focus on a high-quality product coupled with its ongoing efforts to increase supply bode favorably for its growth prospects going forward. For more information, visit the company’s website at www.PacRoots.ca. NOTE TO INVESTORS: The latest news and updates relating to PACR are available in the company’s newsroom at http://ibn.fm/PACR

• Extending the school day could be an important step toward securing a strong future
• Emaginos exclusive DLS system is built around STEM and enriched curriculum that is project based, student centered
• Emaginos’ strength is in providing personalized learning for students with different styles and needs

Research shows compelling evidence that longer school days — and even longer school years — can be beneficial for children. Emaginos Inc. has created a new educational model featuring longer school days and school years. The Emaginos Discovery Learning System (“DLS”) outlines a systemic transformation from the current teacher-centered model to a K-12 public education system focused on encouraging and supporting a student’s desire to learn. “The number-one reason for lengthening the school day is to provide teachers with more time for instruction,” reports a Walden University article (https://ibn.fm/hMqQg). “Over the last century, humans have acquired a staggering amount of knowledge and understanding. It makes sense that we now need to spend more time educating children, especially in the STEM fields, where knowledge is advancing rapidly and where job opportunities remain plentiful. If the U.S. is to stay competitive globally, we must produce an educated populace. Extending the school day could be an important step toward securing a strong future.” Other benefits of longer school days and school years include being more in tune with the modern world and creating a support system for working parents who needed help with childcare. “The 6.5-hour school day — and the long summer break most schools take — originated at a time when children had to help work family farms and ranches,” the Walden article noted. “But keeping this agrarian calendar makes little sense in the information age. If we want to move forward as a nation, we should ensure our children study in a way that complements modern lifestyles and needs.” Of course, providing teachers with more time for instruction is pointless if the instruction isn’t valuable, and that’s where Emaginos shines. In addition to the DLS system incorporating longer school days and school years, the comprehensive system is built around STEM and enriched curriculum that is project based and student centered. The text-free classrooms are focused on hands-on, engaged learning that incorporates state-of-the-art technology. “Emaginos’ strength is in providing personalized learning for students with different styles and needs,” said Dr. Keith Larick, Emaginos’ chief education officer and a national leader in the field of integrating technology into teaching (https://ibn.fm/JCBuH). “Over the past 10 years our three beta test schools have graduated over 1,200 students representing a 96% graduation rate. Emaginos provides the tools for young people to be effective in any profession.” Dedicated to transforming K-12 public schools to a model composed of integrated proven best practices, Emaginos opposes replacing public schools with charter schools or damaging public schools by draining resources through vouchers or school choice programs. Emaginos firmly believes in restoring the concept of the neighborhood schools as the center of the community. For more information, visit the company’s website at www.Emaginos.com. NOTE TO INVESTORS: The latest news and updates relating to Emaginos are available in the company’s newsroom at https://ibn.fm/Emaginos

• During Phase 1 trials, Berubicin showed 44% of patients experienced a clinical benefit of stable disease or better, one being cancer-free after 14 years, and two patients reporting significant tumor reduction (up to 80%)
• Additional research to be conducted by sublicensee partner WPD Pharmaceuticals, Inc. in Poland, including the first-ever pediatric trial
• The glioblastoma multiforme (“GBM”) treatment market is expected to reach $1.4 billion by 2027
• CNS Pharma positioning to secure a leading role in treating GBM

A potentially pivotal Phase 2 trial is on track to commence during Q2 2021 by CNS Pharmaceuticals (NASDAQ: CNSP). This trial is currently planned to include up to 243 subjects, randomized 2:1 (162 Berubicin/81 Lomustine) with an interim analysis when 50% of the subjects reach six months in the study. Berubicin is the lead drug candidate that CNS is working with to use against one of the most aggressive and deadly forms of treatment-resistant cancers that form in the brain – Glioblastoma Multiforme (“GBM”).

GBM is a non-discriminatory type of cancer that can strike any person at any time in their life. Of all primary malignant brain tumors, GBM accounts for 48% of them. Unfortunately, since first identified in the 1920s, the FDA has only ever approved four drugs and one device for GBM treatment. However, none of these FDA-approved approaches have succeeded in increasing life expectancy with GBM more than a few months (https://ibn.fm/JwIWV).

Berubicin is a synthetic 4’-O-Benzylated doxorubicin analog, topoisomerase II Inhibitor, highly cytotoxic, and highly lipophilic. As the first anthracycline to cross the blood-brain barrier, Berubicin was specifically designed to attack a variety of primary brain cancers and cancers metastatic to the brain.

Dr. Waldemar Priebe, Professor of Medicinal Chemistry at The University of Texas MD Anderson Cancer Center, is the original developer of Berubicin. The Phase 1 trial was completed by Reata Pharmaceuticals (NASDAQ: RETA) and showed promising results, with 44% of the trial patients experiencing significant improvement in clinical benefit. One patient from this trial has survived cancer-free for the last 14 years, while two others saw a reduction in tumor size of up to 80 percent.

CNS entered into an asset purchase agreement with Reata in 2017 and as a result holds a worldwide exclusive license to the Berubicin chemical compound and has acquired all the requisite data and know-how from Reata related to the Phase 1 trial.

In addition to the potentially pivotal trial commencing in the United States and expected to expand to include a global footprint, two additional trials are planned in Poland by CNS’s partner WPD Pharmaceuticals. WPD will be conducting two grant-funded studies including one Phase 2 adult GBM trial to commence in Q2 2021 and the first-ever Phase 1 pediatric trial for malignant gliomas set to commence during H2 2021.

CNS hopes to expand Berubicin studies to include other cancers, such as:

• Primary Brain Tumors

• • Relapsed high-grade gliomas with an estimated patient population size of 15,000
• Brain Metastases – Combination with Radiation Therapy
  • Small Cell Lung Cancer has an estimated patient population size of 56,500
  • Non-Small Cell Lung Cancer has an estimated patient population of 56,000
  • Metastatic Breast Cancer has an estimated patient population of 45,000
• CNS Lymphoma
  • 2nd line of defense after Methotrexate failure with a potential 1,200 patient population (there is currently no 2nd line therapy after Methotrexate)

The GBM treatment market is expected to grow from $662 million in 2017 to $1.4 billion in 2027, growing at a CAGR of 7.5% across eight major markets. The eight major markets include the U.S., Germany, Italy, France, Japan, the UK, Spain, and urban China (https://ibn.fm/8tcnS). With Berubicin’s ability to breach the BBB and the planned trials, CNS Pharmaceuticals is uniquely positioned to capitalize on this market growth and secure a leading role in the sector.

The interim Berubicin trial data on the Polish trial in adult GBM patients is expected in the first half of  2022. Multiple value-driving milestones are expected to transpire for CNS Pharmaceuticals during 2021, including growth opportunities for its other drug candidate currently in development, WP1244, a DNA-binding agent believed to be 500 times more potent than daunorubicin in inhibiting tumor cell proliferation, and potentially targeting brain cancers, pancreatic cancers, ovarian cancers, and lymphoma.

For more information, visit the company’s website at www.CNSPharma.com.

NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://ibn.fm/CNSP